The Experts below are selected from a list of 11664 Experts worldwide ranked by ideXlab platform
Yingying Xing - One of the best experts on this subject based on the ideXlab platform.
-
Promoting Immune Efficacy of the Oral Helicobacter pylori Vaccine by HP55/Pbca Nanoparticles against the Gastrointestinal Environment.
Molecular pharmaceutics, 2018Co-Authors: Hai Liu, Wei Liu, Zhoulin Tan, Zhiqin Zeng, Huimin Yang, Shuanghui Luo, Linlin Wang, Yingying XingAbstract:The immunogenicity of oral subunit vaccines is poor partly as a result of the harsh milieu of the gastrointestinal (GI) tract. For some pathogens that restrictedly inhabit the GI tract, a vaccine that works in situ may provide more potent protection than vaccines that operate parenterally. Yet, no appropriate delivery system is available for oral subunit vaccines. In this study, we designed HP55/poly( n-butylcyanoacrylate) (Pbca) nanoparticles (NPs) to carry Helicobacter pylori ( H. pylori) subunit vaccine CCF for oral administration in a prophylactic mice model. These NPs, which are synthesized using an interfacial polymerization method, protected the CCF antigen not only from the acidic pH in simulated gastric fluid (SGF, pH 1.2) but also from the proteolysis in simulated intestinal fluid (SIF, pH 7.4). Oral vaccination of mice with HP55/Pbca-CCF NPs promoted the production of serum antigen-specific antibodies, mucosal secretory IgA, and proinflammatory cytokines. Moreover, a Th1/Th17 response and augmented lymphocytes were found in the gastric tissue of HP55/Pbca-CCF NP-immunized mice, which might eventually limit H. pylori colonization. Collectively, these results indicate that HP55/Pbca NPs are promising carriers against the severe situation of the GI tract and thereby may be further utilized for other orally administrated vaccines or drugs.
-
promoting immune efficacy of the oral helicobacter pylori vaccine by hp55 Pbca nanoparticles against the gastrointestinal environment
Molecular Pharmaceutics, 2018Co-Authors: Hai Liu, Wei Liu, Zhoulin Tan, Zhiqin Zeng, Huimin Yang, Shuanghui Luo, Linlin Wang, Yingying XingAbstract:The immunogenicity of oral subunit vaccines is poor partly as a result of the harsh milieu of the gastrointestinal (GI) tract. For some pathogens that restrictedly inhabit the GI tract, a vaccine that works in situ may provide more potent protection than vaccines that operate parenterally. Yet, no appropriate delivery system is available for oral subunit vaccines. In this study, we designed HP55/poly( n-butylcyanoacrylate) (Pbca) nanoparticles (NPs) to carry Helicobacter pylori ( H. pylori) subunit vaccine CCF for oral administration in a prophylactic mice model. These NPs, which are synthesized using an interfacial polymerization method, protected the CCF antigen not only from the acidic pH in simulated gastric fluid (SGF, pH 1.2) but also from the proteolysis in simulated intestinal fluid (SIF, pH 7.4). Oral vaccination of mice with HP55/Pbca-CCF NPs promoted the production of serum antigen-specific antibodies, mucosal secretory IgA, and proinflammatory cytokines. Moreover, a Th1/Th17 response and augmented lymphocytes were found in the gastric tissue of HP55/Pbca-CCF NP-immunized mice, which might eventually limit H. pylori colonization. Collectively, these results indicate that HP55/Pbca NPs are promising carriers against the severe situation of the GI tract and thereby may be further utilized for other orally administrated vaccines or drugs.
Wei Liu - One of the best experts on this subject based on the ideXlab platform.
-
Promoting Immune Efficacy of the Oral Helicobacter pylori Vaccine by HP55/Pbca Nanoparticles against the Gastrointestinal Environment.
Molecular pharmaceutics, 2018Co-Authors: Hai Liu, Wei Liu, Zhoulin Tan, Zhiqin Zeng, Huimin Yang, Shuanghui Luo, Linlin Wang, Yingying XingAbstract:The immunogenicity of oral subunit vaccines is poor partly as a result of the harsh milieu of the gastrointestinal (GI) tract. For some pathogens that restrictedly inhabit the GI tract, a vaccine that works in situ may provide more potent protection than vaccines that operate parenterally. Yet, no appropriate delivery system is available for oral subunit vaccines. In this study, we designed HP55/poly( n-butylcyanoacrylate) (Pbca) nanoparticles (NPs) to carry Helicobacter pylori ( H. pylori) subunit vaccine CCF for oral administration in a prophylactic mice model. These NPs, which are synthesized using an interfacial polymerization method, protected the CCF antigen not only from the acidic pH in simulated gastric fluid (SGF, pH 1.2) but also from the proteolysis in simulated intestinal fluid (SIF, pH 7.4). Oral vaccination of mice with HP55/Pbca-CCF NPs promoted the production of serum antigen-specific antibodies, mucosal secretory IgA, and proinflammatory cytokines. Moreover, a Th1/Th17 response and augmented lymphocytes were found in the gastric tissue of HP55/Pbca-CCF NP-immunized mice, which might eventually limit H. pylori colonization. Collectively, these results indicate that HP55/Pbca NPs are promising carriers against the severe situation of the GI tract and thereby may be further utilized for other orally administrated vaccines or drugs.
-
promoting immune efficacy of the oral helicobacter pylori vaccine by hp55 Pbca nanoparticles against the gastrointestinal environment
Molecular Pharmaceutics, 2018Co-Authors: Hai Liu, Wei Liu, Zhoulin Tan, Zhiqin Zeng, Huimin Yang, Shuanghui Luo, Linlin Wang, Yingying XingAbstract:The immunogenicity of oral subunit vaccines is poor partly as a result of the harsh milieu of the gastrointestinal (GI) tract. For some pathogens that restrictedly inhabit the GI tract, a vaccine that works in situ may provide more potent protection than vaccines that operate parenterally. Yet, no appropriate delivery system is available for oral subunit vaccines. In this study, we designed HP55/poly( n-butylcyanoacrylate) (Pbca) nanoparticles (NPs) to carry Helicobacter pylori ( H. pylori) subunit vaccine CCF for oral administration in a prophylactic mice model. These NPs, which are synthesized using an interfacial polymerization method, protected the CCF antigen not only from the acidic pH in simulated gastric fluid (SGF, pH 1.2) but also from the proteolysis in simulated intestinal fluid (SIF, pH 7.4). Oral vaccination of mice with HP55/Pbca-CCF NPs promoted the production of serum antigen-specific antibodies, mucosal secretory IgA, and proinflammatory cytokines. Moreover, a Th1/Th17 response and augmented lymphocytes were found in the gastric tissue of HP55/Pbca-CCF NP-immunized mice, which might eventually limit H. pylori colonization. Collectively, these results indicate that HP55/Pbca NPs are promising carriers against the severe situation of the GI tract and thereby may be further utilized for other orally administrated vaccines or drugs.
-
phase transition and elasticity of enstatite under pressure from experiments and first principles studies
Physics of the Earth and Planetary Interiors, 2014Co-Authors: Jennifer Kung, Wei Liu, Robert C LiebermannAbstract:Abstract We have investigated the thermodynamic stability, crystal structure, elastic constants, and sound velocities of MgSiO3-enstatite using data from X-ray diffraction and ultrasonic measurements up to 16.8 GPa and first-principles calculations up to 30 GPa. The calculated enthalpies provide theoretical support for the phase transition from Pbca to P21/c between 9 and 14 GPa previously observed in natural orthoensatite and MgSiO3 enstatite. A density increase of 1.4–1.5% for the Pbca → P21/c transition is obtained from both first-principles and experimental studies. Elastic constants of Pbca, P21/c, C2/c, P21ca and Pbca-II are all calculated, and a softening in the shear constant C55 is predicted for Pbca and Pbca-II phases. C55 of Pbca is found to be closely correlated with the A-site SiO4 tetrahedra chain angle while C44 and C66 are correlated with the B-site chain angle. Pbca, P21/c and C2/c all exhibit similar volumetric compressibilities at all pressures. The calculated velocities of the P21/c phase at 12 GPa are equal to those of Pbca for P and 1.3% higher for S waves. The experimentally observed P and S wave velocity anomalies can be qualitatively described by the transformation from Pbca to P21/c; however, the magnitudes of the velocity decreases between 10 and 14 GPa remain to be verified by future single crystal data or polycrystalline measurements at high pressures. The predicted velocity jumps of 2.8% and 4.5% for P and S waves, respectively, between Pbca and C2/c in the pressure range of 5–12 GPa are in excellent agreement with the values of ∼3(1)% and ∼5(1)% obtained from the directly measured data, thereby making it a plausible candidate for the seismic X-discontinuity at depths of 250–300 km in the Earth’s upper mantle.
Hai Liu - One of the best experts on this subject based on the ideXlab platform.
-
Promoting Immune Efficacy of the Oral Helicobacter pylori Vaccine by HP55/Pbca Nanoparticles against the Gastrointestinal Environment.
Molecular pharmaceutics, 2018Co-Authors: Hai Liu, Wei Liu, Zhoulin Tan, Zhiqin Zeng, Huimin Yang, Shuanghui Luo, Linlin Wang, Yingying XingAbstract:The immunogenicity of oral subunit vaccines is poor partly as a result of the harsh milieu of the gastrointestinal (GI) tract. For some pathogens that restrictedly inhabit the GI tract, a vaccine that works in situ may provide more potent protection than vaccines that operate parenterally. Yet, no appropriate delivery system is available for oral subunit vaccines. In this study, we designed HP55/poly( n-butylcyanoacrylate) (Pbca) nanoparticles (NPs) to carry Helicobacter pylori ( H. pylori) subunit vaccine CCF for oral administration in a prophylactic mice model. These NPs, which are synthesized using an interfacial polymerization method, protected the CCF antigen not only from the acidic pH in simulated gastric fluid (SGF, pH 1.2) but also from the proteolysis in simulated intestinal fluid (SIF, pH 7.4). Oral vaccination of mice with HP55/Pbca-CCF NPs promoted the production of serum antigen-specific antibodies, mucosal secretory IgA, and proinflammatory cytokines. Moreover, a Th1/Th17 response and augmented lymphocytes were found in the gastric tissue of HP55/Pbca-CCF NP-immunized mice, which might eventually limit H. pylori colonization. Collectively, these results indicate that HP55/Pbca NPs are promising carriers against the severe situation of the GI tract and thereby may be further utilized for other orally administrated vaccines or drugs.
-
promoting immune efficacy of the oral helicobacter pylori vaccine by hp55 Pbca nanoparticles against the gastrointestinal environment
Molecular Pharmaceutics, 2018Co-Authors: Hai Liu, Wei Liu, Zhoulin Tan, Zhiqin Zeng, Huimin Yang, Shuanghui Luo, Linlin Wang, Yingying XingAbstract:The immunogenicity of oral subunit vaccines is poor partly as a result of the harsh milieu of the gastrointestinal (GI) tract. For some pathogens that restrictedly inhabit the GI tract, a vaccine that works in situ may provide more potent protection than vaccines that operate parenterally. Yet, no appropriate delivery system is available for oral subunit vaccines. In this study, we designed HP55/poly( n-butylcyanoacrylate) (Pbca) nanoparticles (NPs) to carry Helicobacter pylori ( H. pylori) subunit vaccine CCF for oral administration in a prophylactic mice model. These NPs, which are synthesized using an interfacial polymerization method, protected the CCF antigen not only from the acidic pH in simulated gastric fluid (SGF, pH 1.2) but also from the proteolysis in simulated intestinal fluid (SIF, pH 7.4). Oral vaccination of mice with HP55/Pbca-CCF NPs promoted the production of serum antigen-specific antibodies, mucosal secretory IgA, and proinflammatory cytokines. Moreover, a Th1/Th17 response and augmented lymphocytes were found in the gastric tissue of HP55/Pbca-CCF NP-immunized mice, which might eventually limit H. pylori colonization. Collectively, these results indicate that HP55/Pbca NPs are promising carriers against the severe situation of the GI tract and thereby may be further utilized for other orally administrated vaccines or drugs.
Linlin Wang - One of the best experts on this subject based on the ideXlab platform.
-
Promoting Immune Efficacy of the Oral Helicobacter pylori Vaccine by HP55/Pbca Nanoparticles against the Gastrointestinal Environment.
Molecular pharmaceutics, 2018Co-Authors: Hai Liu, Wei Liu, Zhoulin Tan, Zhiqin Zeng, Huimin Yang, Shuanghui Luo, Linlin Wang, Yingying XingAbstract:The immunogenicity of oral subunit vaccines is poor partly as a result of the harsh milieu of the gastrointestinal (GI) tract. For some pathogens that restrictedly inhabit the GI tract, a vaccine that works in situ may provide more potent protection than vaccines that operate parenterally. Yet, no appropriate delivery system is available for oral subunit vaccines. In this study, we designed HP55/poly( n-butylcyanoacrylate) (Pbca) nanoparticles (NPs) to carry Helicobacter pylori ( H. pylori) subunit vaccine CCF for oral administration in a prophylactic mice model. These NPs, which are synthesized using an interfacial polymerization method, protected the CCF antigen not only from the acidic pH in simulated gastric fluid (SGF, pH 1.2) but also from the proteolysis in simulated intestinal fluid (SIF, pH 7.4). Oral vaccination of mice with HP55/Pbca-CCF NPs promoted the production of serum antigen-specific antibodies, mucosal secretory IgA, and proinflammatory cytokines. Moreover, a Th1/Th17 response and augmented lymphocytes were found in the gastric tissue of HP55/Pbca-CCF NP-immunized mice, which might eventually limit H. pylori colonization. Collectively, these results indicate that HP55/Pbca NPs are promising carriers against the severe situation of the GI tract and thereby may be further utilized for other orally administrated vaccines or drugs.
-
promoting immune efficacy of the oral helicobacter pylori vaccine by hp55 Pbca nanoparticles against the gastrointestinal environment
Molecular Pharmaceutics, 2018Co-Authors: Hai Liu, Wei Liu, Zhoulin Tan, Zhiqin Zeng, Huimin Yang, Shuanghui Luo, Linlin Wang, Yingying XingAbstract:The immunogenicity of oral subunit vaccines is poor partly as a result of the harsh milieu of the gastrointestinal (GI) tract. For some pathogens that restrictedly inhabit the GI tract, a vaccine that works in situ may provide more potent protection than vaccines that operate parenterally. Yet, no appropriate delivery system is available for oral subunit vaccines. In this study, we designed HP55/poly( n-butylcyanoacrylate) (Pbca) nanoparticles (NPs) to carry Helicobacter pylori ( H. pylori) subunit vaccine CCF for oral administration in a prophylactic mice model. These NPs, which are synthesized using an interfacial polymerization method, protected the CCF antigen not only from the acidic pH in simulated gastric fluid (SGF, pH 1.2) but also from the proteolysis in simulated intestinal fluid (SIF, pH 7.4). Oral vaccination of mice with HP55/Pbca-CCF NPs promoted the production of serum antigen-specific antibodies, mucosal secretory IgA, and proinflammatory cytokines. Moreover, a Th1/Th17 response and augmented lymphocytes were found in the gastric tissue of HP55/Pbca-CCF NP-immunized mice, which might eventually limit H. pylori colonization. Collectively, these results indicate that HP55/Pbca NPs are promising carriers against the severe situation of the GI tract and thereby may be further utilized for other orally administrated vaccines or drugs.
Shuanghui Luo - One of the best experts on this subject based on the ideXlab platform.
-
Promoting Immune Efficacy of the Oral Helicobacter pylori Vaccine by HP55/Pbca Nanoparticles against the Gastrointestinal Environment.
Molecular pharmaceutics, 2018Co-Authors: Hai Liu, Wei Liu, Zhoulin Tan, Zhiqin Zeng, Huimin Yang, Shuanghui Luo, Linlin Wang, Yingying XingAbstract:The immunogenicity of oral subunit vaccines is poor partly as a result of the harsh milieu of the gastrointestinal (GI) tract. For some pathogens that restrictedly inhabit the GI tract, a vaccine that works in situ may provide more potent protection than vaccines that operate parenterally. Yet, no appropriate delivery system is available for oral subunit vaccines. In this study, we designed HP55/poly( n-butylcyanoacrylate) (Pbca) nanoparticles (NPs) to carry Helicobacter pylori ( H. pylori) subunit vaccine CCF for oral administration in a prophylactic mice model. These NPs, which are synthesized using an interfacial polymerization method, protected the CCF antigen not only from the acidic pH in simulated gastric fluid (SGF, pH 1.2) but also from the proteolysis in simulated intestinal fluid (SIF, pH 7.4). Oral vaccination of mice with HP55/Pbca-CCF NPs promoted the production of serum antigen-specific antibodies, mucosal secretory IgA, and proinflammatory cytokines. Moreover, a Th1/Th17 response and augmented lymphocytes were found in the gastric tissue of HP55/Pbca-CCF NP-immunized mice, which might eventually limit H. pylori colonization. Collectively, these results indicate that HP55/Pbca NPs are promising carriers against the severe situation of the GI tract and thereby may be further utilized for other orally administrated vaccines or drugs.
-
promoting immune efficacy of the oral helicobacter pylori vaccine by hp55 Pbca nanoparticles against the gastrointestinal environment
Molecular Pharmaceutics, 2018Co-Authors: Hai Liu, Wei Liu, Zhoulin Tan, Zhiqin Zeng, Huimin Yang, Shuanghui Luo, Linlin Wang, Yingying XingAbstract:The immunogenicity of oral subunit vaccines is poor partly as a result of the harsh milieu of the gastrointestinal (GI) tract. For some pathogens that restrictedly inhabit the GI tract, a vaccine that works in situ may provide more potent protection than vaccines that operate parenterally. Yet, no appropriate delivery system is available for oral subunit vaccines. In this study, we designed HP55/poly( n-butylcyanoacrylate) (Pbca) nanoparticles (NPs) to carry Helicobacter pylori ( H. pylori) subunit vaccine CCF for oral administration in a prophylactic mice model. These NPs, which are synthesized using an interfacial polymerization method, protected the CCF antigen not only from the acidic pH in simulated gastric fluid (SGF, pH 1.2) but also from the proteolysis in simulated intestinal fluid (SIF, pH 7.4). Oral vaccination of mice with HP55/Pbca-CCF NPs promoted the production of serum antigen-specific antibodies, mucosal secretory IgA, and proinflammatory cytokines. Moreover, a Th1/Th17 response and augmented lymphocytes were found in the gastric tissue of HP55/Pbca-CCF NP-immunized mice, which might eventually limit H. pylori colonization. Collectively, these results indicate that HP55/Pbca NPs are promising carriers against the severe situation of the GI tract and thereby may be further utilized for other orally administrated vaccines or drugs.